Hearing changes after diagnosis in neurofibromatosis Type 2

Otology and Neurotology

Volumn 25, Issue 2, 2004, Pages 150-154

  Masuda, Ann ^a   Fisher, Laurel M ^a   Oppenheimer, Mark L ^b   Iqbal, Zarina ^a   Slattery, William H ^a  

^a HOUSE EAR INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bilateral; Neurofibromatosis Type 2; Vestibular schwannoma

Indexed keywords

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE COURSE; FEMALE; FOLLOW UP; HEARING; HEARING DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; SPEECH DISCRIMINATION; AUDITORY THRESHOLD; CLINICAL TRIAL; HEARING LOSS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROMA; PATHOPHYSIOLOGY; PRESCHOOL CHILD; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AUDIOMETRY, PURE-TONE; AUDITORY THRESHOLD; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 3142762992     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200403000-00012     Document Type: Article

References (18)

1. Evans DGR. Neurofibromatosis type 2: genetic and clinical features. Ear Nose Throat J 1999;78:97-100.
2. National Institute of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991;9:1-24.
3. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis: II. Guidelines for genetic counseling. J Med Genet 1992;29:847-52.
4. Gutman DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-7.
5. Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope 2000;110:497-508.
6. Tschudi DC, Linder TE, Fisch U. Conservative management of unilateral acoustic neuromas. Am J Otol 2000;21:722-8.
7. Walsh RM, Bath AP, Bance ML, et al. The natural history of untreated vestibular schwannomas: is there a role for conservative management? Rev Laryngol Otol Rhinol 2000;121:21-6.
8. Mirz F, Jorgensen B, Fiirgaard B, et al. Investigations into the natural history of vestibular schwannomas. Clin Otolaryngol 1999;24:13-8.
9. Warrick P, Bance M, Rutka J. The risk of hearing loss in nongrowing, conservatively managed acoustic neuromas. Am J Otol 1999;20:758-62.
10. Yamamoto M, Hagiwara S, Ide M, et al. Conservative management of acoustic neurinomas: prospective study of long-term changes in tumor volume and auditory function. Minim Invasive Neurosurg 1998;41:86-92.
11. Charabi S, Thomsen J, Mantoni M, et al. Acoustic neuroma (vestibular schwannoma): growth and surgical and nonsurgical consequences of the wait-and-see policy. Otolaryngol Head Neck Surg 1995;113:15-4.
12. Jorgensen BG, Pedersen CB. Acoustic neuroma: follow-up of 78 patients. Clin Otolaryngol 1994;19:478-84.
13. Clark WC, Moretz WH, Acker JD, et al. Nonsurgical management of small and intracanalicular acoustic tumors. Neurosurgery 1985;16:801-3.
14. Abaza MM, Makariou EM, Armstrong M, et al. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996;106:694-9.
15. Pikus AT. Pediatric audiologic profile in type 1 and type 2 neurofibromatosis. J Am Acad Audiol 1995;6:54-62.
16. Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma): American Academy of Otolaryngology-Head Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:179-80.
17. Amdur RJ, Biddle CJ. An algorithm for evaluating the ethics of a placebo-controlled trial. Int J Cancer 2001;96:261-9.
18. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995;311:1621-5.